MX2016012752A - Profarmacos de acido succinico para incrementar la produccion de adenosina trifosfato (atp). - Google Patents

Profarmacos de acido succinico para incrementar la produccion de adenosina trifosfato (atp).

Info

Publication number
MX2016012752A
MX2016012752A MX2016012752A MX2016012752A MX2016012752A MX 2016012752 A MX2016012752 A MX 2016012752A MX 2016012752 A MX2016012752 A MX 2016012752A MX 2016012752 A MX2016012752 A MX 2016012752A MX 2016012752 A MX2016012752 A MX 2016012752A
Authority
MX
Mexico
Prior art keywords
permeable
cell
atp
prodrugs
succinates
Prior art date
Application number
MX2016012752A
Other languages
English (en)
Inventor
Joakim Hansson Magnus
Henrik Johannes Ehinger Karl
Moss Steven
Elmér Eskil
Original Assignee
Neurovive Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurovive Pharmaceutical Ab filed Critical Neurovive Pharmaceutical Ab
Publication of MX2016012752A publication Critical patent/MX2016012752A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/40—Succinic acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/18—Eight-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/04—Seven-membered rings not condensed with other rings
    • C07D321/06—1,3-Dioxepines; Hydrogenated 1,3-dioxepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a nuevos succinatos permeables a la célula y precursores de succinato permeables a la célula dirigidos para incrementar la producción de ATP en la mitocondria. La parte principal de ATP producida y utilizada en la célula eucariótica se origina de la fosforilación oxidativa mitocondrial, un proceso al cual se proporcionan electrones de alta energía por el ciclo de Krebs. No todos los intermediarios del ciclo de Krebs son fácilmente permeables a la membrana celular, uno de ellos es succinato. La provisión de nuevos succinatos permeables a la célula se contempla para permitir el pasaje sobre la membrana celular y de este modo los succinatos permeables a la célula pueden ser usados para mejorar el rendimiento de ATP mitocondrial.
MX2016012752A 2014-04-08 2015-04-08 Profarmacos de acido succinico para incrementar la produccion de adenosina trifosfato (atp). MX2016012752A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201470187 2014-04-08
PCT/EP2015/057605 WO2015155230A1 (en) 2014-04-08 2015-04-08 Prodrugs of succinic acid for increasing atp production

Publications (1)

Publication Number Publication Date
MX2016012752A true MX2016012752A (es) 2016-12-12

Family

ID=58762731

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012752A MX2016012752A (es) 2014-04-08 2015-04-08 Profarmacos de acido succinico para incrementar la produccion de adenosina trifosfato (atp).

Country Status (14)

Country Link
US (1) US20170105960A1 (es)
EP (1) EP3129364A1 (es)
JP (1) JP2017518960A (es)
KR (1) KR20160143731A (es)
CN (1) CN106458839A (es)
AU (1) AU2015243345A1 (es)
CA (1) CA2944560A1 (es)
EA (1) EA201692018A1 (es)
IL (1) IL247903A0 (es)
MA (1) MA39856A (es)
MX (1) MX2016012752A (es)
SG (1) SG11201607903UA (es)
WO (1) WO2015155230A1 (es)
ZA (1) ZA201606609B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201692020A1 (ru) 2014-04-08 2017-02-28 Ньюроувив Фармасьютикал Аб Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
RS57624B1 (sr) 2014-04-08 2018-11-30 Neurovive Pharmaceutical Ab Nova sukcinatna jedinjenja koja prodiru u ćelije
WO2017060422A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of mitochondrial disorders
WO2017060418A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases
JP7019590B2 (ja) * 2016-03-31 2022-02-15 バークレー ライツ，インコーポレイテッド 核酸安定化試薬、キット、及びその使用方法
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
CA3113290A1 (en) * 2018-10-11 2020-04-16 Imbria Pharmaceuticals, Inc. Compositions and methods for treating and preventing leber's hereditary optic neuropathy
CN112899328B (zh) * 2021-04-23 2023-06-02 南京同凯兆业生物技术有限责任公司 一种利用酵母全细胞催化合成三磷酸腺苷的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724652B1 (fr) 1994-09-15 1996-12-27 Oreal Utilisation de derives de dehydroalanines pour proteger la peau, les muqueuses et/ou les cheveux du stress oxydant.
GB9612331D0 (en) 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
CN1222139A (zh) * 1996-06-13 1999-07-07 里奥药物制品有限公司 多元醇琥珀酸酯及其药物制剂
AUPR059400A0 (en) 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
JP2014024772A (ja) * 2012-07-25 2014-02-06 Univ Of Tokyo ミトコンドリアのａｔｐ産生能昂進剤
TW201418212A (zh) 2012-10-05 2014-05-16 Mitopharm Ltd 用於增進粒線體製造ａｔｐ之經保護的琥珀酸酯
RS57624B1 (sr) * 2014-04-08 2018-11-30 Neurovive Pharmaceutical Ab Nova sukcinatna jedinjenja koja prodiru u ćelije

Also Published As

Publication number Publication date
US20170105960A1 (en) 2017-04-20
CN106458839A (zh) 2017-02-22
IL247903A0 (en) 2016-11-30
AU2015243345A1 (en) 2016-10-13
KR20160143731A (ko) 2016-12-14
WO2015155230A1 (en) 2015-10-15
MA39856A (fr) 2017-02-15
JP2017518960A (ja) 2017-07-13
SG11201607903UA (en) 2016-10-28
ZA201606609B (en) 2018-05-30
EP3129364A1 (en) 2017-02-15
EA201692018A1 (ru) 2017-04-28
CA2944560A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
MX2016012691A (es) Nuevos compuestos de succinato permeables a la celula.
MA39856A (fr) Promédicaments d'acide succinique pour augmenter la production d'atp
SA519401180B1 (ar) مركبات بيروليزين بها استبدال واستخداماتها
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
CR20160553A (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este
MX2017014351A (es) Un proceso para la preparacion de epoxido de terpinoleno.
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
MY186789A (en) Cathode assembly for the production of aluminum
NZ711192A (en) Process for making benzoxazepin compounds
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
MX368883B (es) Proceso nuevo para la eterificacion de las bis-resorcinil triazinas.
MX2018011877A (es) Proceso mejorado para la preparacion de tartrato de butorfanol.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2018003591A (es) Proceso para preparar 3-metilciclopentadecano-1, 5-diol.
CL2018002149A1 (es) Proceso.
IN2014CH00304A (es)
MX2016013586A (es) Tinturas reactivas fluorescentes, proceso para su produccion y su uso.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
IN2013MU01113A (es)
MY180413A (en) Process for the decomposition of lignocellulose-containing biomass-material
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
CL2020001612A1 (es) Mezclas estables al almacenamiento
PH12019501686A1 (en) Improved process